Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Next Previous
Search
Trial Profile

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Octreotide
  • Indications Gastric cancer; Intestinal cancer; Liver metastases; Neuroendocrine tumours; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NETTER-2
  • Sponsors Advanced Accelerator Applications

    • Most Recent Events

    • 13 Jun 2024 Results investigating the efficacy and safety of first-line [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) treatment. published in the Lancet
    • 04 Jun 2024 Results of sub-analysis of NETTER-2 assessing safety and time to response (TTR), presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 15 May 2024 According to a Novartis media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top